Wegovy results: what the clinical evidence shows and what to expect

What the STEP 1 trial actually measured, and why the numbers matter

Published in the New England Journal of Medicine in 2021, STEP 1 remains the landmark study underpinning Wegovy's UK licence for weight management. The trial ran for 68 weeks. Participants taking semaglutide 2.4mg once weekly lost an average of 14.9% of their body weight, compared with 2.4% for those on placebo. More than two thirds of participants in the active arm lost at least 10% of their starting weight, and around a third lost 20% or more.

Those are population averages. Some people will land above them; others below. Age, starting weight, how consistently the titration schedule is followed, diet and activity levels all influence where an individual ends up. The NHS's patient information on semaglutide makes clear that Wegovy works best alongside genuine lifestyle changes, not instead of them.

The full titration takes around 16 weeks to reach 2.4mg. Weight loss during that period is real but modest, the body is adjusting. Sustained results accumulate from month four onwards for most people. Our page on how long Wegovy takes to work goes into the timeline in more detail if you want a week-by-week breakdown.

The new 7.2mg dose and what it adds to the picture

In January 2026, the MHRA approved a 7.2mg maintenance dose of semaglutide for weight management, initially administered as three 2.4mg pens in a single week. On 14 April 2026, the MHRA approved a dedicated single-dose 7.2mg pen, a purpose-built device with a covered needle that locks after use. Trial data reported around 20.7% average weight loss over 72 weeks at this dose, which puts Wegovy's ceiling results much closer to tirzepatide 15mg than the older 2.4mg ceiling could manage.

The 7.2mg pathway is licensed for adults with a BMI of 30 or above only. It is not available for the cardiovascular indication. Starting dose remains 0.25mg regardless of which maintenance dose is the eventual target, the titration exists to reduce gastrointestinal side effects, and skipping steps is not clinically appropriate. If the higher dose interests you, our Wegovy overview covers the full dose pathway and what a prescriber would consider when deciding whether 7.2mg is right for you.

It is also worth knowing that 7.2mg availability in the private market may vary, specific dose and pen format availability is confirmed during your clinical consultation, not before it.

Early results on Wegovy: the first few weeks

The question we hear most often is some version of: "how quickly will I see something?" The honest answer is that meaningful scale movement for most people starts within the first two to four weeks, though it can be subtle early on. Nausea and reduced appetite often show up before the numbers on the scale shift noticeably, that appetite suppression is part of how semaglutide works.

Many people keeping a close eye on their progress find the first-week experience is less about weight loss and more about adjusting to the medicine. People curious about what Wegovy typically delivers by the two-week mark often find it a useful reality check on what early progress looks like. By week six, most people at 0.5mg or 1mg have started to see a clearer downward trend. The pattern tends to accelerate once titration reaches the higher doses.

Practically speaking, a lot of people keep their pen in the fridge door and take it on the same day each week, Sunday evenings seem popular with our patients. Routine matters because consistency in dosing is one of the strongest predictors of good results on Wegovy.

Getting the best results with Wegovy: what the evidence supports

Semaglutide reduces appetite by slowing gastric emptying and acting on GLP-1 receptors involved in hunger signalling. That creates an opportunity (a quieter appetite makes calorie reduction easier) but the medicine is not doing the work alone. NICE's appraisal of semaglutide (TA875) recommends it only alongside reduced-calorie diet and increased physical activity, with multidisciplinary support where available. The trial results were generated in exactly that context.

Protein intake gets relatively little attention in general discussions of Wegovy results, but it matters. When appetite is suppressed and overall calories fall, maintaining adequate protein helps preserve lean muscle mass, which matters for long-term metabolic health. Hydration is similarly important, particularly during early titration when GI side effects can lead to fluid loss. A prescriber or dietitian can help you think through your diet specifically.

If you are wondering how results on Wegovy compare with tirzepatide (Mounjaro), that is a legitimate question, the SURMOUNT-5 head-to-head trial published in 2025 showed greater average weight reduction with tirzepatide. Our treatment consultation page is the right place to explore which option a prescriber thinks suits your situation. For context on private treatment costs, our Wegovy prices page covers what a private prescription typically includes in the UK.